Melanoma pp 395-410 | Cite as

Spitz Tumors

  • Iwei YehEmail author
  • Boris C. Bastian
Reference work entry


Spitz tumors constitute melanocytic tumors with distinctive epithelioid and spindled melanocytes that typically are benign, but can occasionally metastasize to regional lymph nodes, or in rare situations lead to widespread metastatic dissemination and death. They are characterized by specific genetic alterations such as activating mutations in HRAS or fusion genes that involve kinases such as ALK, ROS1, NTRK1, NTRK3, MET, RET, and BRAF, but lack BRAF V600E and NRAS mutations found in acquired nevi and GNAQ and GNA11 mutations found in blue nevi.


Spitz nevus Atypical Spitz tumor Spitzoid melanoma Fusion kinase HRAS BAP1 


  1. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. Scholar
  2. Argenziano G, Agozzino M, Bonifazi E, Broganelli P, Brunetti B, Ferrara G, Fulgione E, Garrone A, Zalaudek I (2011) Natural evolution of Spitz nevi. Dermatology 222:256–260. Scholar
  3. Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. Scholar
  4. Barnhill RL, Argenyi ZB, From L, Glass LF, Maize JC, Mihm MC, Rabkin MS, Ronan SG, White WL, Piepkorn M (1999) Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 30:513–520CrossRefGoogle Scholar
  5. Bastian BC, Wesselmann U, Pinkel D, Leboit PE (1999) Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol 113:1065–1069. Scholar
  6. Bastian BC, LeBoit PE, Pinkel D (2000) Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 157:967–972. Scholar
  7. Biddle DA, Evans HL, Kemp BL, El-Naggar AK, Harvell JD, White WL, Iskandar SS, Prieto VG (2003) Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol 27:673–681CrossRefGoogle Scholar
  8. Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, LeBoit PE, Burton EA, Bollag G, Ballotti R, Bastian BC (2013) Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res 26:845–851. Scholar
  9. Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, Fu K, Martin BL, Jeck WR, Souroullas GP, Darr DB, Zedek DC, Miley MJ, Baguley BC, Campbell SL, Sharpless NE (2014) Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov 4:1418–1429. Scholar
  10. Busam KJ, Murali R, Pulitzer M, McCarthy SW, Thompson JF, Shaw HM, Brady MS, Coit DG, Dusza S, Wilmott J, Kayton M, Laquaglia M, Scolyer RA (2009) Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol 33:1386–1395. Scholar
  11. Busam KJ, Sung J, Wiesner T, von Deimling A, Jungbluth A (2013) Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes. Am J Surg Pathol 37:193–199. Scholar
  12. Busam KJ, Kutzner H, Cerroni L, Wiesner T (2014) Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions. J Surg Pathol 38:925–933. Scholar
  13. Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H, LeBoit PE, Mihm M Jr, Rosai J, Kerl H (2010a) Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol 34:314–326. Scholar
  14. Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H, LeBoit PE, Mihm M, Rosai J, Kerl H (2010b) Melanocytic tumors of uncertain malignant potential. Am J Surg Pathol 34:314–326. Scholar
  15. Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA (2014) Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene 33:5442–5449. Scholar
  16. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho K-H, Aiba S, Bröcker E-B, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147. Scholar
  17. Da Forno PD, Pringle JH, Fletcher A, Bamford M, Su L, Potter L, Saldanha G (2009) BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br J Dermatol 161:364–372. Scholar
  18. Del Castillo M, Chibon F, Arnould L, Croce S, Ribeiro A, Perot G, Hostein I, Geha S, Bozon C, Garnier A, Lae M, Vincent-Salomon A, MacGrogan G (2015) Secretory breast carcinoma: a histopathologic and genomic spectrum characterized by a joint specific ETV6-NTRK3 gene fusion. Am J Surg Pathol 39:1458–1467. Scholar
  19. Engen-van Grunsven, A C H van, Marcory C R F van Dijk, Dirk J Ruiter, Annelies Klaasen, Wolter J Mooi, and Willeke A M Blokx (2010) “HRAS-Mutated Spitz Tumors: A Subtype of Spitz Tumors with Distinct Features”. The American Journal of Surgical Pathology 34(10):1436–41. Scholar
  20. Farley MN, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie X-J, Dahia PLM, Eng C, Linehan WM, Brugarolas J (2013) A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11:1061–1071. Scholar
  21. Fullen, Douglas R, Jenny N Poynter, Lori Lowe, Lyndon D Su, James T Elder, Rajan P Nair, Timothy M Johnson, and Stephen B Gruber (2006) BRAF and NRAS Mutations in Spitzoid Melanocytic Lesions. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology 19(10):1324–32. Scholar
  22. Gamblin TC, Edington H, Kirkwood JM, Rao UNM (2006) Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features. Ann Surg Oncol 13:1664–1670. Scholar
  23. Gerami P, Scolyer RA, Xu X, Elder DE, Abraham RM, Fullen D, Prieto VG, Leboit PE, Barnhill RL, Cooper C, Yazdan P, Guitart J, Liu P, Pestova E, Busam K (2013) Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol 37:676–684. Scholar
  24. Gill M, Cohen J, Renwick N, Mones JM, Silvers DN, Celebi JT (2004a) Genetic similarities between Spitz nevus and spitzoid melanoma in children. Cancer 101:2636–2640. Scholar
  25. Gill M, Renwick N, Silvers DN, Çelebi JT (2004b) Lack of BRAF mutations in Spitz nevi. J Invest Dermatol 122:1325–1326. Scholar
  26. Herreid PA, Shapiro PE (1996) AGe distribution of spitz nevus vs malignant melanoma. Arch Dermatol 132:352–353. Scholar
  27. Jones DTW, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673–8677. Scholar
  28. Kamino H, Flotte TJ, Misheloff E, Greco MA, Ackerman AB (1979) Eosinophilic globules in Spitz’s nevi. New findings and a diagnostic sign. Am J Dermatopathol 1:319–324CrossRefGoogle Scholar
  29. Kiuru M, Jungbluth A, Kutzner H, Wiesner T, Busam KJ (2016) Spitz tumors comparison of histological features in relationship to immunohistochemical staining for ALK and NTRK1. Int J Surg Pathol 24:200–206. Scholar
  30. Lallas A, Kyrgidis A, Ferrara G, Kittler H, Apalla Z, Castagnetti F, Longo C, Moscarella E, Piana S, Zalaudek I, Argenziano G (2014) Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. Lancet Oncol 15:e178–e183. Scholar
  31. Lallas A, Moscarella E, Longo C, Kyrgidis A, de Mestier Y, Vale G, Guida S, Pellacani G, Argenziano G (2015) Likelihood of finding melanoma when removing a spitzoid-looking lesion in patients aged 12 years or older. J Am Acad Dermatol 72:47–53. Scholar
  32. Lazova R, Pornputtapong N, Halaban R, Bosenberg M, Bai Y, Chai H, Krauthammer M (2017) Spitz nevi and spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas. Mod Pathol. Scholar
  33. Lee, David A, Jason A Cohen, William S Twaddell, Gustavo Palacios, Melissa Gill, Eyal Levit, Alan J Halperin, et al. (2006) “Are All Melanomas the Same? Spitzoid Melanoma Is a Distinct Subtype of Melanoma”. Cancer 106(4):907–13. Scholar
  34. Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A (2015) TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci Rep 5:11200. Scholar
  35. Lohmann CM, Coit DG, Brady MS, Berwick M, Busam KJ (2002) Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 26:47–55CrossRefGoogle Scholar
  36. Luo S, Sepehr A, Tsao H (2011) Spitz nevi and other spitzoid lesions: part II. Natural history and management. J Am Acad Dermatol 65:1087–1092. Scholar
  37. Massi G, LeBoit PE (2014) Histological diagnosis of nevi and melanoma. Springer Berlin Heidelberg, Berlin/HeidelbergCrossRefGoogle Scholar
  38. Menzies AM, Yeh I, Botton T, Bastian BC, Scolyer RA, Long GV (2015) Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res 28:607–610. Scholar
  39. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang H-J, Elashoff R, Faries MB (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599–609. Scholar
  40. Palmedo G, Hantschke M, Rütten A, Mentzel T, Hügel H, Flaig MJ, Yazdi AS, Sander CA, Kutzner H (2004) The T1796A mutation of the BRAF gene is absent in Spitz nevi. J Cutan Pathol 31:266–270CrossRefGoogle Scholar
  41. Paniago-Pereira C, Maize JC, Ackerman AB (1978) Nevus of large spindle and/or epithelioid cells (Spitz’s nevus). Arch Dermatol 114:1811–1823CrossRefGoogle Scholar
  42. Paradela S, Fonseca E, Pita-Fernández S, Prieto VG (2013) Spitzoid and non-spitzoid melanoma in children. A prognostic comparative study. J Eur Acad Dermatol Venereol 27:1214–1221. Scholar
  43. Pellacani G, Scope A, Ferrari B, Pupelli G, Bassoli S, Longo C, Cesinaro AM, Argenziano G, Hofmann-Wellenhof R, Malvehy J, Marghoob AA, Puig S, Seidenari S, Soyer HP, Zalaudek I (2009) New insights into nevogenesis: in vivo characterization and follow-up of melanocytic nevi by reflectance confocal microscopy. J Am Acad Dermatol 61:1001–1013. Scholar
  44. Pol-Rodriquez M, Lee S, Silvers DN, Celebi JT (2007) Influence of age on survival in childhood spitzoid melanomas. Cancer 109:1579–1583. Scholar
  45. Requena C, Requena L, Kutzner H, Yus ES (2009) Spitz nevus: a clinicopathological study of 349 cases. Am J Dermatopathol 31:107–116. Scholar
  46. Sarin KY, Sun BK, Bangs CD et al (2013) Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus. JAMA Dermatol 149:1077–1081. Scholar
  47. Schmoeckel C, Stolz W, Burgeson R, Krieg T (1990) Identification of basement membrane components in eosinophilic globules in a case of Spitz’s nevus. Am J Dermatopathol 12:272–274CrossRefGoogle Scholar
  48. Spatz A (1999) Spitz tumors in children: a grading system for risk stratification. Arch Dermatol 135:282–285. Scholar
  49. Spitz S (1948) Melanomas of childhood. Am J Pathol 24:591–609PubMedPubMedCentralGoogle Scholar
  50. Steiner A, Pehamberger H, Binder M, Wolff K (1992) Pigmented Spitz nevi: improvement of the diagnostic accuracy by epiluminescence microscopy. J Am Acad Dermatol 27:697–701CrossRefGoogle Scholar
  51. Su LD, Fullen DR, Sondak VK, Johnson TM, Lowe L (2003) Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer 97:499–507. Scholar
  52. Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, Bond J, Hill L, Bataille V, Peters G, Kipling D, Wynford-Thomas D, Bennett DC (2003) p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 95:723–732CrossRefGoogle Scholar
  53. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378–381. Scholar
  54. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022–1025. Scholar
  55. Tlougan BE, Orlow SJ, Schaffer JV (2013) Spitz nevi: beliefs, behaviors, and experiences of pediatric dermatologists. JAMA Dermatol 149:283–291. Scholar
  56. van Dijk MCRF, Bernsen MR, Ruiter DJ (2005) Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 29:1145–1151CrossRefGoogle Scholar
  57. Vilain RE, McCarthy SW, Thompson JF, Scolyer RA (2015) BAP1-inactivated spitzoid naevi. Am J Surg Pathol 39:722. Scholar
  58. Weedon D, Little JH (1977) Spindle and epithelioid cell nevi in children and adults. A review of 211 cases of the Spitz nevus. Cancer 40:217–225.<217::AID-CNCR2820400134>3.0.CO;2-2CrossRefPubMedGoogle Scholar
  59. Wiesner T, Murali R, Fried I, Cerroni L, Busam K, Kutzner H, Bastian BC (2012) A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 36:818–830. Scholar
  60. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, Lipson D, Otto G, Brennan K, Murali R, Garrido M, Miller VA, Ross JS, Berger MF, Sparatta A, Palmedo G, Cerroni L, Busam KJ, Kutzner H, Cronin MT, Stephens PJ, Bastian BC (2014) Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 5:3116. Scholar
  61. Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rütten A, Mentzel T, Hügel H, Hantschke M, Schmid-Wendtner M-H, Kutzner H, Sander CA (2003) Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121:1160–1162. Scholar
  62. Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, Mully TW, North JP, Garrido MC, Gagnon A, Vemula SS, McCalmont TH, LeBoit PE, Bastian BC (2015a) Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat Commun 6:7174. Scholar
  63. Yeh I, de la Fouchardiere A, Pissaloux D, Mully TW, Garrido MC, Vemula SS, Busam KJ, LeBoit PE, McCalmont TH, Bastian BC (2015b) Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. Am J Surg Pathol 39:581–591. Scholar
  64. Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, Vemula SS, Garrido MC, Nakamaru K, Isoyama T, McCalmont TH, LeBoit PE, Bastian BC. NTRK3 kinase fusions in Spitz tumours. J Pathol. 2016;240(3):282–290. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Departments of Dermatology and PathologyUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Departments of Dermatology and Pathology, Helen Diller Family Comprehensive Cancer CenterUniversity of California, San FranciscoSan FranciscoUSA

Section editors and affiliations

  • Boris C. Bastian
    • 1
  • Hensin Tsao
    • 2
    • 3
  1. 1.UCSF Helen Diller Family Comprehensive Cancer CenterSan FranciscoUSA
  2. 2.AuburndaleUSA
  3. 3.Harvard-MIT Health Sciences and TechnologyCambridgeUSA

Personalised recommendations